ct-l

CTL-06, a Fatty Acid Synthase (FASN) inhibitor with an IC50 of 3 μM, induces apoptosis, while CTL-12 impedes cell cycle progression in the Sub-G1/S phase and modulates apoptotic and anti-apoptotic markers by upregulating caspase-9 and Bax and downregulating Bcl-xL. Additionally, CTL-12 suppresses de novo lipogenesis, curtailing the metabolic needs of tumor cells, with utilization in breast and colorectal cancer studies [1].

CTL-12, a fatty acid synthase (FASN) inhibitor (IC50: 2.5 μM), induces apoptosis and disrupts the cell cycle at the Sub-G1/S phase. It upregulates caspase-9 and the apoptosis marker Bax, while downregulating the anti-apoptotic marker Bcl-xL. By inhibiting de novo lipogenesis, CTL-12 thwarts tumor cells' metabolic requirements and is frequently employed in breast and colorectal cancer studies [1].

Visugromab (CTL-002) is a monoclonal antibody that targets and neutralises GDF-15. Visugromab exhibits synergistic anticancer activity with the anti-PD1 antibody Nivolumab, making it suitable for PD-1/PD-L1 recurrent/refractory metastatic solid tumours.

Marizomib is a novel irreversible brain-permeable proteasome inhibitor that inhibits CT-L (β5), CT-T-laspase-like (C-L, β1), and trypsin-like (T-L, β2) 20S proteasomes with IC50s of 3.5, 28, and 430 nM.[3]

Ipilimumab (anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor.

Erlotinib (NSC-718781) is an EGFR inhibitor (IC50: 2 nM). It is used for the treatment of non-small cell lung cancer.

Abatacept is a soluble recombinant fusion protein consisting of the extracellular domain of human CTLA-4 and the Fc portion of human IgG1. It binds with high affinity to CD80 and CD86 on antigen-presenting cells, specifically blocking the CD28-mediated costimulatory signal required for T-cell activation. Abatacept is widely used to investigate rheumatoid arthritis, autoimmune responses, and immune dysregulation caused by LRBA deficiency.

ESI-05 (NSC-116966) is a specific EPAC2 (exchange protein directly activated by cAMP 2) antagonist (IC50: 0.4 μM). ESI-05 inhibits cAMP-mediated activation of EPAC2, as well as EAPC2, mediated Rap1 activation.

Lauroyl alanine is a fatty acid amide. It may be used to support the physical gelation of binary mixtures of aliphatic and aromatic hydrocarbon solvents.

CTL26 is an effective, orally active α-glucosidase inhibitor, with an IC50 value of 2.81 µM, demonstrating antidiabetic properties.

B7/CD28 interaction inhibitor 1 (CTLA-4 inhibitor) is a potent CTLA-4 inhibitor.

Boc-Tle-OH is an amino acid derivative and has a wide range of applications in life science related research.

(S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3,3-dimethylbutanoic acid is a useful organic compound for research related to life sciences. The catalog number is T66690 and the CAS number is 132684-60-7.

Letolizumab (BMS-986004) is a dimeric antibody targeting CD40L for the expression of mutant IgG1 that lacks effector functions including Fc binding and complement binding.1 Letolizumab does not induce platelet activation in vitro and does not affect coagulation factors or platelet counts/function after repeated dosing in non-human primates.

Nurulimab (BCD-145) is an anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) human monoclonal antibody with anti-cancer activity for the study of skin and musculoskeletal diseases.

Tremelimumab is a cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) blocking antibody.Tremelimumab is often used in combination with Durvalumab for the treatment of solid cancers such as hepatocellular carcinoma and lung cancer.

Anti-Mouse CTLA-4 Antibody (9D9) is an IgG2b monoclonal antibody that binds CTLA-4, blocking B7 interaction. It enhances T cell function by modulating CD8+/Treg ratios and is used in colon cancer and melanoma research.

Tisagenlecleucel (CTL019), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, selectively targets and eradicates CD19-expressing B cells, and is utilized in the study of refractory aggressive diffuse large B-cell lymphoma [1] [2].

QPCTL-IN-1 (compound 9) serves as a potent inhibitor of the glutaminyl-peptide cyclotransferase-like protein (QPCTL). It is employed in cancer research [1].

Anti-CTLA-4/CD152 Antibody is a humanized monoclonal antibody targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4/CD152). This product specifically binds to the extracellular domain of CTLA-4, blocking its interaction with ligands CD80 (B7-1) and CD86 (B7-2). This blockade removes the negative regulatory signal of CTLA-4 on T-cell activation, thereby enhancing T-cell proliferation, cytokine production, and anti-tumor immune responses.

Anti-CTLA-8/IL-17a Antibody is a human-derived antibody expressed by CHO cells, targeting CTLA-8/IL-17a. It features a huIgG1 heavy chain and a huκ light chain, with an estimated molecular weight (MW) of 150 kDa. For isotype control, refer to HumanIgG1kappa, Isotype Control.

Anti-Mouse CTLA-4 Antibody (9H10) is a Syrian hamster inhibitory antibody that targets CTLA-4.Anti-Mouse CTLA-4 Antibody (9H10) binds to mouse CTLA-4 and blocks the interaction between CTLA-4 and its ligands, showing significant antitumor effects in various tumor models such as breast cancer and colon cancer.

Anti-CTLA-4/CD152 Antibody (BN13) is a mouse chimeric inhibitory antibody that specifically binds to human CTLA-4/CD152.Anti-CTLA-4/CD152 Antibody (BN13) can neutralize CTLA-4 (CD152) and is applicable to studies on infection and immunology, such as human immunodeficiency virus (HIV)-related research .

Anti-Mouse CTLA-4/CD152 Antibody (UC10-4F10-11) specifically binds to mouse CTLA-4（CD152）and promotes T cell costimulation by blocking the interaction between CTLA-4 and B7 coreceptors, thereby enabling the binding of CD28.